Lonza

Lonza, a pharmaceutical preparation manufacturer headquartered in Switzerland (CH), has reported significant greenhouse gas (GHG) emissions. For 2025, the company's total emissions were approximately 2.71 billion kg CO2e. This figure is composed of Scope 1 emissions totalling about 317 million kg CO2e, Scope 2 emissions (market-based) of approximately 93 million kg CO2e, and substantial Scope 3 emissions reaching about 2.30 billion kg CO2e. The largest contributors to Lonza's Scope 3 emissions in 2025 were purchased goods and services (approximately 1.53 billion kg CO2e) and capital goods (approximately 304 million kg CO2e).

In 2024, Lonza's total emissions were around 2.36 billion kg CO2e, with Scope 1 emissions at approximately 343 million kg CO2e, Scope 2 (market-based) at about 141 million kg CO2e, and Scope 3 at approximately 1.88 billion kg CO2e.

Lonza has established ambitious climate commitments, aiming to align with a 1.5°C pathway. The company has committed to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, using a 2021 baseline. Lonza also aims for a 50% reduction in GHG intensity per revenue by 2030, with a baseline year of 2018. Furthermore, Lonza is working to ensure that 79% of its suppliers, representing purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028. The company's overarching ambition is to achieve net-zero emissions by 2050 or earlier.